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DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orches-
trates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating
miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs
and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 in-
teracts with AGO2 to induce or reduce AGO2’s association of a subset of miRNAs, including multiple let-7 family mem-
bers. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family
miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the onco-
genic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage–induced in-
crease in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global
miRNA–mRNA interaction networks involved in the DNA damage response, validating them through the identification
of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of
the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose
cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of reg-
ulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2–miRNA interaction represents a new
mechanism of miRNA regulation in carcinogenesis.
[Supplemental material is available for this article.]
DNA damage activates TP53, which acting principally as a tran-
scription factor, directs DNA repair or, where irreparable damage
has occurred, the initiation of programmed cell death. It does so
by orchestrating the transcription of a number of messenger
RNAs (mRNAs) (Menendez et al. 2009), noncoding RNAs—both
long noncoding RNAs (lncRNAs) (Hung et al. 2011) and
microRNAs (miRNAs)—which are involved in controlling these
pathways (Krell et al. 2013). TP53 also modulates the nuclear bio-
genesis step of a group ofmiRNAs by interactingwith theDROSHA
complex through the DEAD box RNA helicase DDX5 (Suzuki et al.
2009). A number of chemotherapeutic agents with anti-cancer ac-
tivity act as DNA damaging agents, including doxorubicin (DOX),
which induces double-strand DNA breaks (DSBs) that activate
TP53-mediated cell signaling pathways such as apoptosis, senes-
cence, and cell cycle arrest (Krell et al. 2013; Kruiswijk et al.
2015). DOX is widely used to activate DNA damage in cell lines
in order to study TP53 function.
Mutations in, or inactivation of, TP53 are the most frequent
abnormalities observed in cancer cells (Hollstein et al. 1991).
Furthermore, miRNAs are often dysregulated in cancer, indicating
that refining our knowledge of their roles in TP53-signaling net-
works and their gene targets is crucial to achieving a greater under-
standing of tumorigenesis.
Importantly, miRNAs only become active regulators of their
mRNA targets once they interact with AGO1-4 proteins, the key
components of the RNA-induced silencing complexes (RISCs).
When loaded with a miRNA, AGO proteins inhibit the expression
of their targets, recognizing them throughmiRNA-target base-pair-
ing (Bartel 2009).
Isolation and sequencing of RNAs (RNA-seq) that interact
with AGO proteins has been widely performed to globally identify
functional miRNA targets in vivo at single nucleotide resolution.
These include photoactivatable-ribonucleoside-enhanced cross-
linking and immunoprecipitation followed by deep sequencing
(PAR-CLIP-seq), high-throughput sequencing of RNA isolated by
crosslinking immunoprecipitation (HITS-CLIP), individual-nucle-
otide resolution crosslinking and immunoprecipitation (iCLIP),
and finally, RNA immunoprecipitation followed by deep sequenc-
ing (RIP-seq) (Chi et al. 2009; Hafner et al. 2010; Konig et al. 2011;
Schraivogel et al. 2011). More recently these techniques have been
coupled with crosslinking, ligation, and sequencing of hybrids6Joint first authors
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(CLASH), a technique involving a ligation reaction during the RNA
preparation step to covalently join miRNAs to the RNA regions
with which they interact (Helwak et al. 2013; Helwak and
Tollervey 2014). Following this procedure, the bioinformatic isola-
tion and analysis of the chimeric products allows the unambigu-
ous identification of miRNA targets (Helwak et al. 2013;
Grosswendt et al. 2014; Helwak and Tollervey 2014).
Importantly, despite that regulation ofmiRNA biogenesis has
been extensively explored, both at the transcription and matura-
tion levels, to the best of our knowledge, modulation of the asso-
ciation between miRNAs and the RISC complex upon cellular
stimulation has not been previously demonstrated. In light of
this, we hypothesized that modulation of miRNA association
with AGO2 could be a further step in the regulation of miRNA ac-
tivity upon specific cellular stimuli. Thus, we aimed to investigate
whether such a mechanismmight represent a novel TP53-mediat-
ed process, capable of regulating miRNA activity in a different
manner to those previously described, and with relevance to the
DNA-damage response and carcinogenesis.
Results
TP53 regulates the association between a subgroup
of miRNAs and AGO2
To evaluate if DNAdamage induced byDSBs affects the association
between certain miRNAs and the RISC complex, we stimulated ei-
ther TP53+/+ or TP53−/− HCT116 human colon cancer cell lines
with DOX for 24 h and performed small RNA-seq from total
RNA and from RNA purified from immunoprecipitated AGO2
(AGO2-RIP-seq), analyzed using a tailored bioinformatics pipeline
(Supplemental Fig. S1; Supplemental Methods). As illustrated in
Supplemental Figure S2A, a number ofmiRNAs exhibited a statisti-
cally significant, TP53-dependent increase or decrease in cellular
abundance (Benjamini-Hochberg adjusted Student’s t-test P-value
< 0.05) following DOX treatment. Here, we confirmed the TP53-
dependent up-regulation of miR-34a, miR-143, andmiR-107, con-
sistent with previous findings (He et al. 2007; Suzuki et al. 2009)
supporting the reliability of our approach (Supplemental Fig.
S2A; Supplemental Table S1). However, a number of miRNAs
demonstrated an increase or decrease in cellular abundance in
both TP53+/+ and TP53−/− cells following DOX treatment (Supple-
mental Fig. S2B; Supplemental Table S1), indicating that these
expression changes occurred in a TP53-independent manner.
Interestingly, our small RNA-seq approach identified, for the first
time, that miR-3065-3p and miR-3065-5p are the miRNAs most
strongly up-regulated by DNA damage (Supplemental Fig. S2B;
Supplemental Table S1). This occurred in a TP53-independent
manner (Supplemental Fig. S2B; Supplemental Table S1), indicat-
ing that these miRNAs could be central to the DNA damage re-
sponse, and we validated this finding by RT-qPCR (Supplemental
Fig. S2C).
Strikingly, although for many miRNAs, their increase in
abundance on AGO2 correlated with an increase in cellular expres-
sion (marked “&”) (Fig. 1A,B), for a subset, DNA-damage modulat-
ed their association with AGO2 (Benjamini-Hochberg adjusted
Student’s t-test P-value < 0.05) but not their cellular abundance
(marked “o” ) (Fig. 1A,C; Supplemental Fig. S3A). This occurred
in a TP53-dependent manner (Fig. 1A,C) as no change in miRNA
association with AGO2 was seen in HCT116 TP53−/− cells (Fig.
1D). Interestingly, at least threemembers of the let-7 family exhib-
ited such increases in AGO2 binding (Fig. 1A,C; Supplemental
Fig. S3A) that were not due to changes in AGO2 expression (Sup-
plemental Fig. S3B). To increase our confidence in defining the
miRNAs whose abundance was regulated by DNA damage, we
only considered those whose expression was changed in a compa-
rable manner in both the AGO2-RIP-seq and the RNA-seq experi-
ments (Fig. 1A, marked “&”; and Fig. 1B). Briefly, we identified
10miRNAs that were up-regulated and 2 that were down-regulated
in a TP53-dependent manner (marked “&”) (Fig. 1A,B), and six
miRNAs that were up-regulated and three that were down-regulat-
ed independently of TP53 (marked “&”) (Fig. 1D). Furthermore, we
identified 26miRNAswhose associationwith AGO2 increased and
15 whose association with AGO2 decreased following DOX treat-
ment, without their expression levels changing, finding that this
only occurred in the presence of wild-type TP53 (marked “o”)
(Fig. 1A,C; Supplemental Table S1).
The association of AGO2 with let-7 family miRNAs
is significantly increased in response to DOX in the
presence of wild-type TP53 but is decreased in the presence
of mutant TP53
The role of let-7 miRNAs in repressing cell cycle and cancer pro-
gression has been demonstrated by several independent groups
(Boyerinas et al. 2010). However, their abundance has not been
found to change in response toDSBs stimulated byDOX treatment
in HCT116 cells in this (Figs. 1B,C; Supplemental Fig. S2A; Supple-
mental Table S1) or previous high-throughput studies (Chang et al.
2007; He et al. 2007; Suzuki et al. 2009). Strikingly, our results in-
dicate a novel mechanismwhereby, instead ofmodulating the cel-
lular abundance of the let-7 family, DSBs increase the association
between these miRNAs and AGO2. Having identified a TP53-de-
pendent modulation of AGO2 binding for three members of the
let-7 family and considering their roles in negatively regulating
cell cycle progression,we subsequently examined expression levels
of all let-7 family members in our small RNA-seq and RIP-seq data.
Specifically, we compared the changes in the expression levels
induced by DNA damage (i.e., log-fold changes of DOX-treated
versus untreated samples) between total RNA and AGO-immuno-
precipitated RNA data for both TP53+/+ and TP53−/− cells. This re-
vealed a significant TP53-dependent regulatory effect on the
association between AGO2 and the entire let-7 family apart from
let-7d (Fig. 2A), and we validated these findings by RT-qPCR (Fig.
2B,C). The cellular abundance of both let-7f and let-7g was un-
changed during a time course experiment following 1–24 h of
DOX treatment (Fig. 2D), indicating that the TP53-dependent in-
crease in their association with AGO2 demonstrated after 24 h
treatment was not due to an earlier and transient increase in let-
7 expression within the treatment period.We also confirmed a de-
creased association between miR-148a-5p and AGO2 in response
to DOX treatment (Fig. 2E), whereas no significant change in
miR-148a-5p expression was observed in a time course experiment
(Supplemental Fig. S3C). Strikingly, the association between let-
7c or let-7i and AGO2 significantly increased in both HCT116
TP53+/+ (Fig. 2A,B) and wild-type RKO human colon cancer
cell lines (Fig. 2F) but did not change inDLD1human colon cancer
cell lines that expressed a mutated form of TP53 (Fig. 2F).
Reintroduction of wild-type TP53 into HCT116 TP53−/− cells re-
stored both the induction of miR-34a and the increased associa-
tion between let-7 and AGO2 in response to DOX (Fig. 2G).
Noticeably, the introduction of two mutant TP53 proteins
(R175H and R248W) into HCT116 TP53−/− cells, which have
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Figure 1. TP53 is required for DNA damage–inducedmodulation of the association between AGO2 and a subset of miRNAs. (A) Bar plot of fold changes
for 53miRNAs exhibiting statistically significant (Benjamini-Hochberg adjusted Student’s t-test P-value < 0.05) differential expression of small RNAs isolated
from immunoprecipitated AGO2 after DOX treatment. In some cases (12/53 miRNAs marked by an “&” symbol in the bar plot x-axis labels), the observed
changes in levels of AGO2 binding reflect changes in abundance in total RNA induced by the treatment. In other cases (41/53 miRNAs marked by an “o”
symbol in the bar plot x-axis labels), however, the observed changes in AGO2 binding occur in the absence of changes in abundance in total RNA. (B)
Scatterplot showing miRNAs that change significantly in both the AGO2-immunoprecipitation and total RNA samples (HCT116 TP53+/+ cells). (C)
Scatterplot showing miRNAs that significantly change in the AGO2-immunoprecipitation but not in the total RNA samples (HCT116 TP53+/+ cells). (D)
Bar plot of fold changes for nine miRNAs exhibiting statistically significant (Benjamini-Hochberg adjusted Student’s t-test P-value < 0.05) and TP53-inde-
pendent changes in expression. For these miRNAs, changes in AGO2 binding reflect changes in abundance in total RNA (9/9 miRNAs marked by an “&”
symbol in the bar plot x-axis labels). In A andD, each bar represents themean and standard deviation of three biological replicates. In B and C, thicker dotted
gray lines indicate the selected log-fold change cutoff (0.35), and thinner dotted gray lines indicate a log-fold change equal to 0.
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been shown to exert oncogenic instead of tumor suppressive activ-
ity (Liu et al. 2010), significantly reduced the association between
let-7 and AGO2 (Fig. 2G), while a third TP53 mutant (R273H) lost
its capacity to affect this association.
TP53 interacts with AGO2 in both the cytoplasmic and nuclear
compartments following DOX-mediated DSBs
Co-IP experiments indicated that wild-type and mutant TP53 var-
iants all interact with AGO2 after DOX treatment (Fig. 3A,B).
Interestingly, the interaction between AGO2 and TP53 was de-
creased after RNase treatment, alongside increases in the unbound
supernatant (Fig. 3C), indicating that RNAs enhance the AGO2–
TP53 association. The interaction between TP53 and AGO2 was
previously demonstrated in a genome-wide association study in
Drosophila melanogaster (Lunardi et al. 2010), demonstrating that
this cobinding is highly conserved across species. Next, we used
a proximity ligation assay (PLA) in untreated and DOX-treated
cells to evaluate the cellular compartment in which this binding
occurs, following DNA damage (Fig. 4A). We found that TP53 in-
teracted with AGO2 after 24 h of DOX treatment (Fig. 4A), consis-
tent with our demonstration of a TP53-dependent mechanism
regulating the association between AGO2 and a subgroup of
miRNAs (Fig. 1A,C). Interestingly, AGO2-TP53 complexes were
present in both the cytoplasm and the nucleus following 24 h of
DOX treatment (Fig. 4A,C), but the majority were located in
the nucleus (Fig. 4A,C), indicating that additional functions
may be exerted by this complex in the nuclear compartment.
Accordingly, it has been previously demonstrated that DICER1-
and DROSHA-dependent functional small RNAs arise from
DSBs (Francia et al. 2012). This, coupled with our results, suggests
that AGO2 may interact with this small RNA population in the
Figure 2. DOX-induced DNA damage induces TP53-dependent differential binding of specific miRNAs to AGO2. (A) Fold changes in let-7 family levels
determined by a combined small RNA-seq and AGO2-RIP-seq approach (miRNAs demonstrating a positive or negative fold change equal to or greater than
the selected cutoff of 0.35 [log2] and a t-test P-value < 0.05 after correcting for multiple testing with the Benjamini-Hochberg method [Benjamini and
Hochberg 1995], were considered to be significant). (B,C ) RT-qPCR analysis demonstrates that the binding of let-7 family members onto AGO2 is increased
significantly in HCT116 TP53+/+ but not in TP53−/− cells following DOX treatment. (D) Time course showingmiR-34a and let-7 family fold changes follow-
ing DOX-induced DNA damage in total RNA extracted fromHCT116 TP53+/+ cells. (E) Fold change in miR-148-5p expression in total RNA or AGO2-bound
RNA samples following an AGO2 IP in DOX- or vehicle-treated HCT116 TP53+/+ and TP53−/− cell lines. (F) Fold change in let-7 and miR-34a expression
following an AGO2 IP in DLD1 and RKO cell lines following DOX-induced DNA damage. (G) Fold change in let-7 family and miR-34a expression following
an AGO2 IP in HCT116 TP53−/− cells transfectedwith plasmids expressingwild-type ormutant TP53 (R175H, R248W, R273H). (IN) RNA isolated from input
samples; (IP) RNA isolated from the immunoprecipitated AGO2; (null) HCT116 TP53−/− cells; (WT) HCT116 TP53−/− cells transfected with the plasmid
expressing wild-type TP53; (R175H) HCT116 TP53−/− cells transfected with the plasmid expressing R175H TP53 mutant; (R248W) HCT116 TP53−/− cells
transfected with the plasmid expressing R248W TP53 mutant; (R273H) HCT116 TP53−/− cells transfected with the plasmid expressing R273H TP53 mu-
tant. At least three independent experiments have been performed in all cases.
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nucleus. AGO2 was actively imported into the nucleus upon
DOX treatment, independently of TP53 (Supplemental Fig. S4A,
B). The absence of fluorescent spots over the background level
in HCT116 TP53−/− cells indicated the existence of a specific
interaction (Fig. 4B). AGO2–TP53 binding occurred in response
to DOX in both wild-type (Figs. 3A, 4A,C) and TP53 mutant
expressing cells (Fig. 3B), but the TP53-dependent effect on the
let-7’s association with AGO2 was different in cells with mutant
TP53 (Fig. 2G).
A set of transcripts, whose cellular abundance
does not change following the induction of DSBs,
are differentially associated with AGO2
Next, we wished to determine the mRNA targets of the DNA dam-
age–regulated miRNAs. It is known that TP53 directly activates the
transcription of several genes (Wei et al. 2006) in response to DNA
damage. However, very little is known about the fraction of genes
that do not change at the transcriptional level but that are post-
transcriptionally regulated in response toDNAdamage. To identify
genes that may be post-transcriptionally regulated through an
AGO2–miRNA interaction, but are not transcriptionally modulat-
ed, we performed RNA-seq and AGO2-RIP-seq of polyadenylated
transcripts (Supplemental Fig. S5; Supplemental Table S2). As
expected, our RNA-seq showed extensive deregulation of genes
involved in apoptosis, DNA damage response, and cell cycle
(Supplemental Fig. S6A–F; Supplemental Table S3) as well as previ-
ously described TP53 targets (Supplemental Fig. S6A). Consistent
with our previous findings (Krell et al. 2014), expression of
snoRNAs derived from the GAS5 locus was also increased via
TP53 (Supplemental Table S2). Notably, by combining our RNA-
seq and AGO2-RIP-seq data, we identified 144 and 161 genes,
whose binding onto AGO2 increased and decreased, respectively,
in response to DNA damage in both replicates, but whose expres-
sion showed no change in total RNA samples (Supplemental Fig.
S6G), indicating that these genes are post-transcriptionally regulat-
ed throughaDNAdamage–mediatedmiRNA–AGO2-target interac-
tion. Apathwayenrichment analysis involving these twogroups of
genes did not show any significant category of gene enrichment
when the P-values were adjusted for multiple hypothesis testing.
Nevertheless, we noticed that among the transcripts that were
more associated with AGO2 (indicative of increased repression by
miRNAs) following DNA damage, at least eight code for proteins
that negatively regulate apoptosis (Supplemental Fig. S7A).
Conversely, among the transcripts less associatedwith AGO2 (pos-
sibly because their repression bymiRNAs was released) in response
to DSBs, there were at least nine that code for proteins involved in
DNA repair (Supplemental Fig. S7B), demonstrating that this regu-
lation might be important for the DNA damage response.
In addition, among the transcripts that were either more or
less associated with AGO2 following DOX treatment, 31 are anno-
tated as lncRNAs and 12 as pseudogenes (Supplemental Table S2),
suggesting that competing activity between miRNAs and noncod-
ing RNAs (Poliseno et al. 2010; de Giorgio et al. 2013) might occur
during theDNAdamage response.NEAT1was among the lncRNAs
whose association with AGO2 was reduced by DNA damage
(Supplemental Table S2). This lncRNA is essential for the forma-
tion of paraspeckles (Clemson et al. 2009), which have been impli-
cated in cancer cell survival (Choudhry et al. 2015).
Importantly, transcripts that were more associated with
AGO2 in response to DNA damage were significantly enriched
for let-7 seed matches (Supplemental Table S4), indicating that
the aforementioned TP53-induced association between let-7 and
AGO2 is functional.
PAR-CLIP-seq identifies the mRNA targets of those miRNAs
modulated by DSBs
To identify the mRNA targets of those miRNAs modulated by
DSBs, we treated HCT116 TP53+/+ and TP53−/− cells with DOX
and performed an AGO2 PAR-CLIP-seq experiment. After UV
crosslinking, partial RNase digestion, and AGO2 IP, we prepared
small RNA libraries from nine replicates per treatment. We used
Figure 3. AGO2 interacts with TP53 in an RNA-dependent manner.
HCT116 TP53+/+ were treated with vehicle or DOX for 12 h, and coimmu-
noprecipitation assays were then performed to determine whether an in-
teraction exists between TP53 and AGO2 proteins. (A) Reciprocal co-IP
experiments using AGO2 and TP53 antibodies demonstrate an interaction
between the two proteins. DDX5was used here as a positive control for the
immunoprecipitation, and ACTBwas used as a loading control housekeep-
ing gene in the input sample. (B) To test the impact of mutations in TP53
on its ability to interact with AGO2, TP53−/− cells were transfected with
empty plasmid (null) or plasmids expressing mutated forms of TP53
(R175H, R248W, and R273H), treated with DOX for 12 h, and subjected
to co-IP. (C) To investigate whether the association between TP53 and
AGO2 is RNA-dependent, immunoprecipitates of AGO2 and TP53 from
cells treated with DOX for 12 h were digested with increasing quantity
of RNase A for 30 min at 37°C, separated into supernatant and beads,
and analyzed by immunoblotting. At least three independent experiments
have been performed in all cases.
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the PARalyzer tool (Corcoran et al. 2011) to identify genome-wide
AGO2 interaction sites from our PAR-CLIP data based on the rate
of T to C conversions and read density and obtained a total of
111,841 clusters of reads, representing AGO2 binding sites from
all of the sequenced libraries (corresponding to a unique set of
54,256 sites). We then annotated the collection of AGO2 binding
sites obtained to genomic regions to evaluate AGO2 binding dis-
tribution and observed a neat binding preference for 3′ untran-
slated regions (3′ UTRs) and coding DNA sequences (CDSs)
(Supplemental Fig. S8A). In fact, it is known that miRNAs enact
post-transcriptional repression of targets through interacting
with coding CDSs (Tay et al. 2008) as well as 3′ UTRs and
5′ UTRs (Lytle et al. 2007). Since clusters of reads derived from
PAR-CLIP are selected by identifying T to C conversion sites (see
Methods), they disproportionately arise from T-rich regions. This
indicates that the AGO2 distribution in the various parts of the
genes needs to be adjusted for T frequency in PAR-CLIP analysis.
To this end, we calculated the nucleotide frequency from 5′ UTR,
CDS, and 3′ UTR sequence annotations used here to map the
PAR-CLIP sequencing reads (Supplemental Fig. S8B). As expected,
Ts were more enriched in the 3′ UTRs than the CDSs (T frequency
equal to 29.68% and 21.78%, respectively) (Supplemental Fig.
S8B), and we used their frequencies to normalize PAR-CLIP cluster
distribution (Supplemental Fig. S8C). After normalizing for T con-
tent, we found that AGO2 was almost equally distributed between
3′ UTR and CDS regions (Supplemental Fig. S8C).
Subsequently, we analyzed occurrences of short sites match-
ing the reverse-complement of miRNA canonical seed regions
(Lewis et al. 2005), along with their evolutionary conservation,
to assign AGO2 binding sites identified by the PAR-CLIP analysis
to miRNAs. In accordance with previous findings (Hafner et al.
2010), the positional distribution of the first miRNA recognition
element (MRE) nucleotide in each AGO2 binding site showed a
preference for positions from −2 to +5 with respect to the predom-
inant T to C transition within the clusters (Supplemental Fig. S9),
andwe used this information togetherwithMRE conservation and
length to prioritize the assignment of a single expressed miRNA
to each AGO2 binding site where there was ambiguity due to mul-
tiple possibleMREs (seeMethods for further details). SincemiRNAs
also target genes in a “noncanonical”manner, through bulges and
G:U pairs in the seed region (Chi et al. 2012; Helwak et al. 2013;
Clark et al. 2014), and given our novel findings of an increased as-
sociation between let-7 and AGO2 following DNA damage, we
wished to complement our analysis by taking into account poten-
tial noncanonical interactions between let-7 and their gene targets
on AGO2. To achieve this, we used the miRNA–mRNA interaction
data from Clark and coworkers (available at https://cm.jefferson.
edu/clip_2014/) that contains HITS-CLIP results from multiple
cell lines (Clark et al. 2014), focusing on let-7 interactions and se-
lecting those that overlapped with our AGO2 binding sites
(Supplemental Table S5). Finally, based on the analysis of AGO2
binding sites and their assignment to targeting miRNAs, we built
a comprehensivemiRNA–mRNA interactionnetwork (Supplemen-
tal Fig. S10). Noticeably, this miRNA-targetome network showed
coregulation of genes important for cell cycle progression, includ-
ing CCND1 and POGZ that were targeted by multiple up-regulated
miRNAs and by let-7 members (Supplemental Fig. S10; Supple-
mental Table S5).Wevalidated by luciferase reporter assays the reg-
ulatory interaction of four differentmiRNAs (namely let-7a, let-7d,
miR-23a, and miR-34) that appeared to putatively coregulate both
CCND1 and POGZ (Supplemental Fig. S11). Among these, the
only experimentally validated interaction absent in the PAR-
CLIP interaction network was the one between miR-34a and
POGZ. Nevertheless, we also included this potential interaction
in the reporter analysis because of the relevance of miR-34a for
the DNA damage response (He et al. 2007) and because an 8-mer
matching to the miR-34a seed in the POGZ 3′ UTR is conserved
among vertebrates (Supplemental Fig. S11).
Figure 4. DNA damage increases the interaction between TP53 and AGO2 both in the cytoplasm and in the nucleus. (A) TP53-AGO2 PLA in HCT116
TP53+/+ cells shows that TP53 interacts with AGO2 after 24 h of DOX treatment, and this interaction also occurs in the cytoplasm but is predominantly
observed in the nucleus. (B) Absence of green spots over background level in TP53−/− HCT116 cells indicates that the interaction shown by the PLA in
wild-type cells, after 24 h of DOX treatment (A) is specific. (C ) Bar plot showing quantification of PLA spots in the cytoplasm and in the whole HCT116
wild-type cells. Slides were imaged using a Leica TCS SP5 confocal laser-scanning microscope and analyzed using ImageJ software. The number of PLA
foci was manually counted in a blind fashion (100 cells per each condition in each of three independent experiments). Cytoplasmic foci were defined
as fluorescent spots that did not colocalize with the nuclei stained with DAPI (two-tailed Student’s t-test). At least three independent experiments have
been performed in all cases.
Krell et al.
336 Genome Research
www.genome.org
 Cold Spring Harbor Laboratory Press on June 15, 2018 - Published by genome.cshlp.orgDownloaded from 
We then extracted themiRNA–mRNApairs specific for the ac-
tivated (either more abundant or more associated with AGO2) and
repressed (either less abundant or less associated with AGO2)
miRNAs in response to DSBs to evaluate the miRNA–mRNA inter-
action subnetworks regulated by DSBs (Supplemental Fig. S10,
bottom left and top right subnetworks). Since coordinated tran-
scription andmiRNA-mediated post-transcriptional repression en-
hances robustness of gene regulation in mammals (Tsang et al.
2007), we wanted to evaluate the global overall impact of miRNA
regulation on gene expression in response to DSBs. To this end,
we highlighted with green (down-regulation) or red (up-regula-
tion) coloring the gene expression changes elucidated by RNA-
seq for genes involved in the networks of miRNA–mRNA interac-
tions derived from the PAR-CLIP data analysis (Supplemental
Fig. S10).We used this approach to evaluate how thesemiRNAs co-
ordinately affect genes that are up- or down-regulated following
DSBs by other mechanisms, such as transcription. It appeared
that miRNAs activated by DSBs targeted genes that were both
up-regulated and down-regulated by the DNA damage itself
(Supplemental Figs. S10, S12; Supplemental Table S5), indicating
that after their activation, these miRNAs modulate the damage re-
sponse through an intricate network of regulatory feedback and
feedforward loops, supporting publishedmodels of miRNA regula-
tion (O’Donnell et al. 2005; Tsang et al. 2007; Castellano et al.
2009). Interestingly, the subnetwork relative to targets of the
let-7 family members (Supplemental Fig. S10, bottom right;
Supplemental Table S5) was enriched for cell cycle and TP53-sig-
naling pathways (Fig. 5A). This indicates that the TP53-dependent
increase in binding of let-7 family members with AGO2 actively
participates in the DSB response.
let-7-mRNA chimeric reads from PAR-CLIP-seq are significantly
more abundant after DOX treatment in TP53 wild-type cells
compared with untreated cells
We then implemented a computational pipeline to identify un-
equivocal interactions between miRNAs and their targets by ana-
lyzing the miRNA–mRNA fusion products (chimeras) originating
from endogenous ligase activity during the PAR-CLIP procedure
(Fig. 5B; Supplemental Fig. S13; Supplemental Table S6; Gross-
wendt et al. 2014). Analysis of the distribution of the last nucleo-
tide in both the miRNA and the target region of the selected
chimera candidates confirmed a highprevalence ofG (Supplemen-
tal Fig. S14A), as previously shown (Grosswendt et al. 2014). In ad-
dition, the target region of the identified chimeras substantially
map to 3′ UTR regions, in contrast to the PAR-CLIP data that
showed a similar frequency of miRNA interactions in 3′ UTRs
and CDSs (Supplemental Figs. S8C, S14B). This indicates that
miRNA–mRNA chimeras could be preferentially formed from 3′
UTR regions. We were unable to identify interactions for many
abundant miRNAs, suggesting that the ligation between miRNAs
and targets occurs more frequently for some miRNAs than others.
We also observed that the sequences corresponding to the target
regions obtained from the chimeras harbor a seed match for the
cognate miRNA far more frequently than found in a set of random
sequences (Supplemental Fig. S14C).
As expected, when we extended the sequences of the target
part of the chimeras (to look for seed matches, as RNase digestion
often shortens their length), we found that 5-mer matches com-
plementary to the miRNA seed region occurred much more fre-
quently than when adding random nucleotides (Supplemental
Fig. S14C). Notably, 5-mer matches were more frequent than
both 6- and 7-mers combined (Supplemental Fig. S14C), suggest-
ing that 5-mers alone in the seed may be of great relevance for
miRNA-target interaction.
Separately, and also as expected, 4-mer windows of comple-
mentarity to the target were most often enriched from the second
position of 5′ end of themiRNA (Supplemental Fig. S15) again sup-
porting the chimeras as bona fide target-miRNA hybrids.
Motif enrichment analysis of the chimera target sites indicat-
ed that those recognized by let-7 members tend to havemore con-
sistent perfect base-pairing to positions 3, 4, and 7 of the miRNA-
seed region compared to other nucleotides in the seed, which
show higher mismatch frequency (Fig. 5C; Supplemental Fig
S14A,B), although different members of the let-7 family appear
to have a slightly different recognition modes (Fig. 5D; Supple-
mental Fig S16A,B). Interestingly, by plotting the positional distri-
bution of the best match for each motif identified as enriched in
let-7c and let-7b target sequences, we found that the motif corre-
sponding to the seed region was centered, with a peak between
the center (0) and the −10 position of the analyzed data set of tar-
get sequences (Supplemental Fig. S16C,D). Notably, only let-7c
targets were associated with U-rich motifs peaking next to the
miRNA–mRNA “seed” interaction sites (Supplemental Fig. S13C,
position between−30 and−20 of the graph), indicating that an ad-
ditional RNA binding protein(s) might contribute to let-7c-mRNA
target regulation. Importantly, the percentage of formed let-7c-5p-
target chimeric reads significantly increased with DOX treatment
(Fig. 5D), once again confirming that the TP53-dependent increase
in interaction between let-7 family members and AGO2 function-
ally influences the DNA damage regulated miRNA-targetome.
Discussion
In this study, we identified an unprecedented role for TP53 in in-
teracting with AGO2 and modulating the association between a
subset of miRNAs and AGO2 during the DNA damage response.
Although a recent study demonstrated that hypoxia suppressed
AGO2-mediated maturation of a group of miRNAs (Shen et al.
2013), to the best of our knowledge, our data represents the first ev-
idence that an external stimulus could impact the association be-
tween specific miRNAs and AGO2, and this mechanism is
unrelated to variations in their abundance. This indicates that an
AGO2–miRNA interaction but not regulation ofmiRNAbiogenesis
is responsible. In particular, we found that the expression levels of
specific let-7 family members, which usually act as tumor suppres-
sor miRNAs negatively regulating cell cycle and differentiation
processes (Boyerinas et al. 2010), are not differentially expressed
following DSBs caused by DOX treatment. Rather, we observed
modulation of the association of these and other miRNAs with
the RISC complex. Moreover, we used state-of-the-art whole-ge-
nome techniques (including RIP-seq and PAR-CLIP-seq) and com-
putational methods (such as the determination of miRNA–mRNA
chimeras formed by endogenous ligase activity during the PAR-
CLIP procedure) (Grosswendt et al. 2014) to evaluate the targeting
networks of the DOX-regulated miRNAs. Using these techniques,
we found that mRNAs that were more bound onto AGO2 follow-
ing DOX treatment (indicative of miRNA post-transcriptional reg-
ulation mediated by the DNA damage response) were enriched for
let-7 seedmatches.We shouldmention that due to the selection of
T-to-C conversions during PAR-CLIP analysis, sites lacking Us in
the clusters of reads could have been missed.
Importantly, the let-7-mRNA chimeras that formed upon
DOX treatment were significantly more abundant in DOX-treated
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samples in TP53+/+ but not TP53−/− cells. These results indicate
that a TP53-mediated increase of let-7 miRNAs’ association with
AGO2 following DOX treatment functionally influences the re-
pression of their targets. Consistentwith this finding, the let-7-reg-
ulated gene signature that we discovered showed functional
enrichment in cell cycle and TP53-signaling pathways. Notably,
we found thatmismatches in the seed of let-7members did not oc-
cur randomly, but were seen with much greater frequency at spe-
cific positions. Our finding that 5-mer seed matches represent a
higher proportion of the miRNA-targetome than 6-mer and
7-mermatches combined indicates that thismode ofmiRNA bind-
ing could be sufficient for miRNA regulation more often than is
currently appreciated.
Furthermore, we showed that various oncogenic mutant
forms of TP53 decreased miRNA binding onto AGO2 rather than
increasing it, as observed for wild-type TP53. This suggests an ad-
ditional oncogenic mechanism through which these mutant
TP53 variants function that implies loss of their capability to me-
diate let-7 association with AGO2 following DNA damage.
Although the mechanism by which TP53 might regulate the asso-
ciation of certainmiRNAs with AGO2 remains unknown, it is pos-
sible to speculate that TP53 interacting with AGO2 may modify
Figure 5. let-7-mRNA chimeras are significantly more abundant after DOX treatment in TP53 wild-type cells compared with untreated cells. (A)
KEGG pathways enrichment analysis performed using clusterProfiler (https://www.bioconductor.org/packages/3.3/bioc/html/clusterProfiler.html)
(Yu et al. 2012) for the list of genes included in the let-7 subnetwork. (B) Circos (http://circos.ca/) (Krzywinski et al. 2009) circularly layered heatmaps
and histograms from different experiment data tracks produced in the present study mapped on the human genome (hg19). From outer to inner
circle: heatmap of gene expression changes found in DOX-treated versus vehicle-treated TP53+/+ HCT116 cells by RNA-seq of total and AGO2-bound
RNA samples; gene expression changes found in DOX-treated versus vehicle-treated TP53−/− HCT116 cells by RNA-seq of total and AGO2-bound RNA
samples; heatmap of miRNA expression changes found in DOX-treated versus vehicle-treated TP53+/+ HCT116 cells by small RNA-seq of total and
AGO2-bound RNA samples; miRNA expression changes found in DOX-treated versus vehicle-treated TP53−/− HCT116 cells by small RNA-seq of total
and AGO2-bound RNA samples; histogram of changes in PAR-CLIP cluster abundance in DOX-treated versus vehicle-treated samples for HCT116
TP53+/+ cells. Data tracks in the figure render values of observed log-fold changes on a green (lower values) to red (higher values) scale. Ribbons in the
circle center show miRNA-target interactions identified by analysis of chimera reads (i.e., ligation products, including part of the mature miRNA and
part of its binding site sequence) from the PAR-CLIP experiments. (C ) Result of motif analysis performed by using MEME (http://meme.nbcr.net/
meme/) (Bailey et al. 2015) on the chimera target sites identified for let-7c. (D) Bar plots of the percentage of total chimera reads in DOX-treated samples
compared to vehicle-treated samples.
Krell et al.
338 Genome Research
www.genome.org
 Cold Spring Harbor Laboratory Press on June 15, 2018 - Published by genome.cshlp.orgDownloaded from 
the conformation of AGO2 or other RISC components and conse-
quently change their affinity for a subset of miRNAs. Furthermore,
the variable effect onmiRNA–AGO2 associations that we observed
using TP53 mutants suggests that TP53’s regulation of AGO2
binding may be dependent of its conformation, since these mis-
sense mutants can have local (R248W and R273H) or more com-
prehensive (R175H) conformational changes (Sigal and Rotter
2000). In conclusion, this report reveals a novel role for TP53 in
regulating the DNA damage response, demonstrating an addition-
al mechanism of miRNA regulation with relevance to cancer
progression.
Methods
Plasmid transfection, RT-qPCR, 3′ UTR luciferase reporter assay,
bioinformatic processing of the RNA-seq data, and the statistical
approaches as well as additional details are provided in the
Supplemental Methods.
Cell culture and DOX treatment
HCT116 TP53+/+ and TP35−/−, DLD1, and RKO cell lines were
maintained in Dulbecco’s modifed Eagle’s medium or McCoy’s
medium supplemented with 10% FCS, 1% penicillin/streptomy-
cin, and 2% glutamine. Cells were plated in 150-mm dishes at
50% confluence and incubated at 37°C in a humidified 5%CO2 in-
cubator. They were then treated with DOX at a concentration of
0.2 µg/mL or equivalent volume of vehicle (ddH2O). After each
treatment time point, dishes were placed on ice and medium was
aspirated. Cells were washed twice with cold PBS, scraped, and
centrifuged for 5 min at 1300 rpm. The supernatant was removed,
and the cell pellet was processed for RNA using TRIzol reagent
(Invitrogen) and/or protein extraction.
Preparation of the RNA and small RNA libraries
RNA and small RNA libraries were produced using the Illumina
TruSeq RNA Sample Prep Kit and Small RNA Sample Prep Kit, re-
spectively (Illumina), according to the manufacturer’s protocols.
For both procedures, 200 ng RNA was used from the immuno-
precipitation samples and 4 µg from the input samples. For
the RNA sequencing (RNA-seq), paired-end sequences (reads) of
100 nt in length were then generated using a HiSeq 2000 instru-
ment (Illumina). For the small RNA-seq, single-end reads of 50
nt in length were generated using a HiSeq 2000 instrument
(Illumina).
AGO2 RNA immunoprecipitation (RIP)
Cells were plated and treated with DOX at a concentration of
0.2 µg/mL or equivalent volume of vehicle for 24 h. Cells were
washed in cold PBS, scraped, and then lysed with a buffer contain-
ing 0.5% Nonidet, 0.5 mMDTT, 20 mM Tris-HCL pH7.5, 150 mM
KCL, 2 mM EDTA, 1 mMNaF, and inhibitors of RNases, proteases,
and phosphatases. Ten percent of total lysate was removed and
kept as the input samples and the remainder used for immunopre-
cipitation. Ten micrograms of anti-AGO2 (11A9, SAB4200085,
Sigma-Aldrich) or anti-IgG (Sigma-Aldrich) antibodies were bound
to sepharose beads in the presence of heparin. Precleared lysates
were then incubated with the appropriate antibody-bound beads,
and the immunoprecipitated proteins were thenwashed and incu-
bated with DNase I in the presence of DNase buffer (Promega)
followed by protease K (New England Biolabs) in the presence of
2× protease buffer (New England Biolabs). RNA extraction was
then performed using phenol chloroform separation and etha-
nol/sodium acetate precipitation. RNA pellets were washed in eth-
anol and quantified using a Nanodrop.
AGO2 PAR-CLIP
PAR-CLIP was performed as previously described (Hafner et al.
2010) with minor modifications. Briefly, a total of 400 million
cells were used for each experiment. Each plate was treated
with 4-Thiouridine (Sigma-Aldrich) at a final concentration of
100 µM 14 h prior to UV-crosslinking with 0.15 J/cm2 of 365-
nm UV light with a Stratalinker UV Crosslinker (Stratagene).
Cells were then scraped, lysed, and digested with RNase T1
(Fermentas) to a final concentration of 1 unit/µL. AGO immuno-
precipitation of the lysate was then performed using Dynabeads
Protein G magnetic particles (Invitrogen) and AGO antibody
(Sigma) at a final concentration of 0.05 µg/µL. A second RNase
T1 treatment was then performed using a final concentration of
10 units/µL. The RNA segments were then radiolabeled using
32P-γATP to a final concentration of 0.5 µCi/µL and T4 PNK to a
final concentration of 1 unit/µL, and samples were then resus-
pended in 70 µL SDS-PAGE loading buffer, and SDS-PAGEwas per-
formed. The gel bands corresponding to AGO were cut for each
sample and electroelution of the crosslinked RNA–protein com-
plexes was then performed. Recovery of crosslinked target RNA
fragments was then performed using phenol chloroform and eth-
anol extraction.
Co-IP and RNase treatment
Cells were plated and treated with DOX at a concentration of
0.2 µg/mL or equivalent volume of vehicle for 24 h unless stated.
After washing with cold PBS, cells were scraped following lysing
with RIPA buffer. Ten percent total lysate was removed and
kept as the input samples, and the remainder was used for im-
munoprecipitation following ImmunoCruz Optima Immunopre-
cipitation protocol, provided with Optima B and C (Santa Cruz
Biotechnology). Preclearing Matrix B and C were used for optimal
preclearing of the lysate (Santa Cruz Biotechnology). The follow-
ing antibodies were used during the immunoprecipitation and
immunoblotting: anti-TP53 (DO-1, sc-126; Santa Cruz); anti-
AGO2 (ab32381, Abcam); anti-DDX5 (ab21696, Abcam); IgG
(Santa Cruz).
To check for RNA dependence in TP53–AGO2 interaction,
matrix-bound complexes were incubated with RNase A (Sigma)
for 30 min at 37°C. Following incubation, samples were spun
down and separated into supernatant- and bead-containing frac-
tions and subjected to immunoblot analysis.
Immunofluorescence
Following treatment with DOX, cells were fixed with 4% para-
formaldehyde in PBS for 10 min, the excess of which was sub-
sequently quenched with 0.5 M glycine in PBS for 20 min at
room temperature (RT). For cell permeabilization, 0.3% Triton
X-100 was added for 10 min. Next, cells were incubated with
blocking buffer (5% goat serum, 1% BSA, 2% FCS in PBS) for 30
min followed by incubation with mouse monoclonal anti-
TP53 antibody (1:100; sc-126, Santa Cruz) and rabbit polyclonal
anti-AGO2 (1:250; ab32381, Abcam) for 1 h at RT. Cells
were washed three times with 1% BSA and 2% FCS in PBS and
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incubated with Alexa 488 (anti-rabbit; Invitrogen) and 568
(anti-mouse; Invitrogen) for 2 h at RT. Next, cells were washed
twice with 1% BSA and 2% FCS in PBS and incubated with 4%
paraformaldehyde for 10 min at RT. Samples were subsequently
washed twice with PBS and mounted using Mowiol 4-88
(Calbiochem) with DAPI. Slides were analyzed using a Leica TCS
SP5 confocal laser-scanning microscope and analyzed using
ImageJ software.
Duolink proximity ligation assay (PLA)
After treatment with DOX, fixation, permeabilization, blocking,
and primary antibody incubation steps were performed as de-
scribed in the immunofluorescence section. Once cells were
washed three times with 1% BSA and 2% FCS in PBS, incubation
with PLA probes (i.e., anti-rabbit PLUS, anti-mouse MINUS PLA
probes), ligation, amplification, and mounting of the coverslips
were all performed according to the manufacturer’s instruction
(Sigma-Aldrich). Slideswere imaged using a Leica TCS SP5 confocal
laser-scanning microscope and analyzed using ImageJ software.
The number of PLA foci was manually counted in a blind fashion
(100 cells per each condition in the three independent experi-
ments). Cyto-3 plasmic foci were defined as fluorescent spots
that did not colocalize with the nuclei stained with DAPI.
Statistical significance in the number of PLA foci was tested by us-
ing a two-tailed t-test.
Data access
Sequencing data from this study have been submitted to the
European Nucleotide Archive (ENA; http://www.ebi.ac.uk/ena),
under accession numbers PRJEB3157 and PRJEB3233 for small
and long RNAs sequencing data, and PRJEB3396, for PAR-CLIP
data.
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